

New bioinformatics platform introduced

Illumigen Biosciences Inc., the United States, has launched a new initiative in computational analysis. The new analysis platform, code-named GeneLamp™, is a combination of genetic, genomic and statistical analyses that sorts through Human Genome Project data in conjunction with proprietary experimental work carried out at Illumigen's laboratories.

This program aims to speed up discovery efforts by increasing the efficiency with which one can evaluate and prioritize promising new drug targets. The GeneLamp platform is optimized to take advantage of the specialized genomics work being conducted in-house at Illumigen. These efforts are focused on detecting particular patterns in DNA sequence and gene expression data collected using Illumigen's population access programmes. GeneLamp automatically seeks out information, from a variety of databases, that is complementary to Illumigen's data for analysing the two data sets together, resulting in a highly validated list of potential drug targets. (GEN News, 2 February 2001)